May. 7 at 7:42 PM
Is the obesity race entering a new phase of competition?
$NVO is reportedly scaling up its pursuit of “for-sale” obesity assets, at a level potentially larger than the
$PFE–Metsera deal.
At the same time, sentiment around
$LLY’s orforglipron is becoming more divided, with modest efficacy and potential liver toxicity concerns emerging.
While Lilly has been active in early-stage obesity acquisitions, it is now facing growing competitive pressure from Novo’s more cost-efficient oral approach, especially as U.S. patient adoption expands.
However, how long this dynamic lasts remains uncertain.
Strategically, it seems unlikely that Lilly will remain passive in the next obesity M&A cycle, unlike its previous stance during the Metsera bidding situation.
Free sharing and subscription 👉 @StockMacroView.
